BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged violations of securities laws, specifically related to misleading statements about its drug candidates [1][4]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Biohaven made false and misleading statements regarding the regulatory prospects of its drug candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder [4]. - The class period for the lawsuit is defined as March 24, 2023, to May 14, 2025, during which investors are encouraged to participate if they suffered losses [2]. Group 2: Investor Information - Investors who purchased Biohaven's securities during the class period are urged to contact the Schall Law Firm before September 12, 2025, to discuss their rights [2][3]. - The class has not yet been certified, meaning that until certification occurs, affected investors are not represented by an attorney [3].